FDA Approves One-Pill, Once-Daily HIV Treatment

Tue, 04/05/2011 - 5:13am

Boehringer Ingelheim Pharmaceuticals, Inc. announced that the FDA has approved Viramune XRT (nevirapine) extended-release tablets, a one-pill, once-daily (400 mg) formulation of nevirapine for use in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults.

"With the approval of once-daily VIRAMUNE XR, patients in the U.S. now have the benefit of a new HIV treatment option for use in combination with their other HIV medications," said Joseph Gathe, Jr., M.D., clinical instructor, Department of Internal Medicine, Baylor College of Medicine and lead investigator of the VERxVE clinical trial. "Physicians in the U.S. can now switch their current VIRAMUNE patients to a once-daily product with demonstrated comparable safety and efficacy."



Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.